Dana Devine | |
---|---|
Alma mater | Boston University (BA, MA) Duke University (PhD) |
Awards | Queen’s Golden Jubilee Award [1] 2015 Ortho Award, Canadian Society for Transfusion Medicine [2] AABB Hemphill-Jordan Leadership Award, 2021 [3] |
Scientific career | |
Fields | Transfusion medicine |
Institutions | AABB University of British Columbia Canadian Blood Services |
Dana Devine was a blood transfusion researcher and the president of AABB. [2] She was the editor-in-chief of Vox Sanguinis from 2012 to 2020. [4] Devine was also the Chief Scientist at Canadian Blood Services [2] and the director of the Centre for Blood Research at the University of British Columbia. [5] In 2015, she was elected as a fellow of the Canadian Academy of Health Sciences. [6] In 2022, she was elected as the President of the Biomedical Excellence for Safer Transfusion Collaborative. [7]
Under the direction of Dr. Wendell F. Roose, Devine received her Ph.D. in immunology from Duke University in 1986. [8] [9] She previously completed a bachelor's degree in biology and a master's degree in marine biology, both at Boston University. [10]
Devine first joined Canadian Blood Services (CBS) in 1999, following its creation as a result of the Krever Inquiry, as the executive director of research and development. [10] As director, she was instrumental in the development of the CBS’ accomplished Centre for Innovation, including its netCAD Blood4Research facility in Vancouver which is recognized globally for its work to drive innovation in transfusion medicine by collecting blood for research in blood collection, manufacturing, and storage. [11] [12] Other countries are taking inspiration from this model, including the U.S. and Australia. [11] She was vice-president of medical, scientific, and research affairs for 11 years before becoming Chief Scientist. [13] Her work at CBS included improvements to testing for transfusion transmitted infection, donor and transplantation services, surveillance and epidemiology, and improvements to platelet unit manufacturing processes. [11] [13] Also in response to the Krever Inquiry, Devine co-founded the Centre for Blood Research in 2002. [14] In 2021, she became its director. [15]
Devine was elected president of AABB in 2020 and took office in October 2021. [2] [13] She was previously a vice-president of AABB. [16] An AABB member since 1998, Dana recognized the challenges that the field was facing, including the maintenance of a stable and adequate blood supply, ensuring a sufficient and well-trained workforce, and advancing research. [17] As President, Devine committed to being an advocate for research in this field, suggesting that the challenges being faced could be addressed through innovation. [17]
For her "critical scientific leadership to Canada’s blood system," Devine was elected a fellow of the Canadian Academy of Health Sciences in 2015. [6]
Devine joined the University of British Columbia's Department of Pathology and Laboratory Medicine in 2000, and served as the Graduate Studies Program Director. [18]
Devine's research specialties were in blood system management and quality improvement, [2] platelet biology and coagulation, and complement biochemistry. [10] She was President of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative, where her projects focused on improving the processing, quality, and utilization of conventional blood components. [7] [19] [20] She attended her first BEST meeting in 2002, subsequently joining the Conventional Components team under the direction of Dr. Sherrill Slitchter and Nancy Heddle. [7] Following this she co-led the team with Dr. Pieter van der Meer. [7] Devine's efforts with BEST as an executive led to the publishing of papers in notable journals. [7] As President, Devine was keen on leading Best Collaborative to address pressing issues in the community including the loss of DEHP from blood storage containers and reminding blood operators of the need to revalidate everything that they make. [7]
Her laboratory at the University of British Columbia was focused on improving the storage quality of platelet units. [10] Devine was also involved in research on the use of convalescent plasma to treat COVID-19, [21] as well as research using Raman spectroscopy to assess the quality of stored red blood cells. [22] [23]
Devine was a member of various boards for biotechnology companies and blood operators. Devine was the chair of the medical advisory board for Macopharma, a transfusion product company based in Lille, France. [7] She also served as a member of the board of directors for a gene therapy start-up based in Boston, US, STMR.Bio. [24] She sat on the research advisory boards for blood operators, including the Australian Red Cross Lifeblood, Vitalant, and the Bloodworks Northwest (formerly Puget Sound Blood Centre). [7] Devine chaired the medical advisory committee for the largest blood operator in the United States, the American Red Cross.
Devine was credited with over one-hundred paper publications in scientific journals. [25] Her publications have garnered over ten-thousand citations. [26] Her most cited paper is title "Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions", with over 400 citations. [26]
Devine retired from Canadian Blood Services in 2023. [27] She passed away on November 12, 2024. [28] In 2024, Canadian Blood Services and the Canadian Society of Transfusion Medicine jointly introduced the Dana Devine Award to further careers in transfusion research. [29] [30]
Blood transfusion is the process of transferring blood products into a person's circulation intravenously. Transfusions are used for various medical conditions to replace lost components of the blood. Early transfusions used whole blood, but modern medical practice commonly uses only components of the blood, such as red blood cells, plasma, platelets, and other clotting factors. White blood cells are transfused only in very rare circumstances, since granulocyte transfusion has limited applications. Whole blood has come back into use in the trauma setting.
Transfusion medicine is the branch of medicine that encompasses all aspects of the transfusion of blood and blood components including aspects related to hemovigilance. It includes issues of blood donation, immunohematology and other laboratory testing for transfusion-transmitted diseases, management and monitoring of clinical transfusion practices, patient blood management, therapeutic apheresis, stem cell collections, cellular therapy, and coagulation. Laboratory management and understanding of state and federal regulations related to blood products are also a large part of the field.
A blood bank is a center where blood gathered as a result of blood donation is stored and preserved for later use in blood transfusion. The term "blood bank" typically refers to a department of a hospital usually within a clinical pathology laboratory where the storage of blood product occurs and where pre-transfusion and blood compatibility testing is performed. However, it sometimes refers to a collection center, and some hospitals also perform collection. Blood banking includes tasks related to blood collection, processing, testing, separation, and storage.
A blood donation occurs when a person voluntarily has blood drawn and used for transfusions and/or made into biopharmaceutical medications by a process called fractionation. A donation may be of whole blood, or of specific components directly (apheresis). Blood banks often participate in the collection process as well as the procedures that follow it.
AABB is an international, not-for-profit organization representing individuals and institutions involved in the field of transfusion medicine and biotherapies.
Canadian Blood Services is a non-profit charitable organization that is independent from the Canadian government. The Canadian Blood Services was established as Canada's blood authority in all provinces and territories except for Quebec in 1998. The federal, provincial and territorial governments created the Canadian Blood Services through a memorandum of understanding. Canadian Blood Services is funded mainly through the provincial and territorial governments.
Transfusion-related acute lung injury (TRALI) is the serious complication of transfusion of blood products that is characterized by the rapid onset of excess fluid in the lungs. It can cause dangerous drops in the supply of oxygen to body tissues. Although changes in transfusion practices have reduced the incidence of TRALI, it was the leading cause of transfusion-related deaths in the United States from fiscal year 2008 through fiscal year 2012.
Platelet transfusion, also known as platelet concentrate, is used to prevent or treat bleeding in people with either a low platelet count or poor platelet function. Often this occurs in people receiving cancer chemotherapy. Preventive transfusion is often done in those with platelet levels of less than 10 x 109/L. In those who are bleeding transfusion is usually carried out at less than 50 x 109/L. Blood group matching (ABO, RhD) is typically recommended before platelets are given. Unmatched platelets, however, are often used due to the unavailability of matched platelets. They are given by injection into a vein.
The International Society of Blood Transfusion (ISBT) is a scientific society founded in 1935 which promotes the study of blood transfusion and provides information about the ways in which blood transfusion medicine and science can best serve patients' interests. The society's central office is in Amsterdam, and there are around 1900 members in 103 countries. As of June 2024, the president of the ISBT is Pierre Tiberghien.
The Health Sciences Authority (HSA) is a statutory board under the Ministry of Health of the Government of Singapore. It is a multi-disciplinary agency responsible for applying medical, pharmaceutical, and scientific expertise to protect and advance public health and safety.
Platelet transfusion refractoriness is the repeated failure to achieve the desired level of blood platelets in a patient following a platelet transfusion. The cause of refractoriness may be either immune or non-immune. Among immune-related refractoriness, antibodies against HLA antigens are the primary cause. Non-immune causes include splenomegaly, fever, and sepsis.
Patient Blood Management (PBM) is a set of medical practices designed to optimise the care of patients who might need a blood transfusion. Patient blood management programs use an organized framework to improve blood health, thus increasing patient safety and quality of life, reducing costs, and improving clinical outcomes. Some strategies to accomplish this include ensuring that anemia is treated prior to a surgical operation, using surgical techniques that limit blood loss, and returning blood lost during surgery to the patient via intraoperative blood salvage.
Carter BloodCare is a 501(c)(3) nonprofit organization headquartered in Bedford, Texas. Carter BloodCare currently provides more than 440,000 blood products annually to over 200 hospitals serving patients in more than 50 counties across North, Central and East Texas. One of the largest blood centers in operation in the United States, Carter BloodCare’s mission is “we save lives by making transfusion possible.”.
Mark Elliot Brecher is a physician specializing in pathology, in particular blood transfusion.
George William Gregory Bird was a British medical doctor, academic, researcher and haematologist known for his expertise in the fields of blood transfusion and immunohaematology. He founded the Department of Transfusion Medicine at the Armed Forces Medical College, Pune and was inducted into their Hall of Fame in 2010. A winner of the Karl Landsteiner Memorial Prize and Morten Grove Rasmussen Memorial Award of the American Association of Blood Banks, Gregory Bird was honoured by the Government of India in 1963, with the award of Padma Shri, the fourth highest Indian civilian award for his services to the nation.
Single unit transfusion refers to transfusing a single unit or bag of blood product to a person who is not bleeding and haemodynamically stable followed by an assessment to see if further transfusion is required.. The benefits of single unit transfusion include reduced exposure to blood products. Each unit transfused increases the associated risks of transfusion such as infection, transfusion associated circulatory overload and other side effects. Transfusion of a single unit also encourages less wastage of blood products and can be cost-effective. Single unit transfusion can be as part of an institutional or national guidelines and instituted with the help of a transfusion committee or transfusion practitioner. Education of medical staff is important and catch phrases such as "Why use two when one will do", "every ONE matters" or "one bag is best - then reassess" have been used.
Marion Elizabeth Reid is a British scientist specialising in immunohematology and author based in Bristol. She has worked in both the United Kingdom and the United States.
Yvette Marie Miller is an American physician specializing in transfusion medicine who is known for her advocacy for sickle cell patients and increasing blood donations in the Black community.
Sherrill Slichter is an American physician whose work on platelet biology earned her transfusion medicine’s three highest honors: the AABB Karl Landsteiner Memorial Award; International Society of Blood Transfusion Presidential Award; and the British Blood Transfusion Society James Blundell Award.
Anneke Brand (1946-2021) was a Dutch physician-scientist whose work on platelet and red blood cell transfusion and cord blood transplantation earned her transfusion medicine’s three highest honors: the AABB Karl Landsteiner Memorial Award; International Society of Blood Transfusion Presidential Award; and the British Blood Transfusion Society James Blundell Award.
{{cite web}}
: CS1 maint: multiple names: authors list (link)